^
    Back
    Association details:
    Biomarker:CRLF2 rearrangement
    Cancer:Acute Lymphocytic Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

    Excerpt:
    ...CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+) 2....
    Trial ID:
    AALL1521
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

    Excerpt:
    ...- Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type)...
    Trial ID:
    NCT03571321
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Leukemia
    Title:

    Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia

    Published date:
    04/24/2021
    Excerpt:
    ...we conducted preclinical in vivo drug testing and demonstrated that ruxolitinib enhanced the in vivo efficacy of an induction-type regimen consisting of vincristine, dexamethasone, and L-asparaginase in 2/3 CRLF2-rearranged Ph-like ALL xenografts.
    Secondary therapy:
    LVD
    DOI:
    10.1038/s41375-021-01248-8